Ernest Moles
Dr. Ernest Moles is a multidisciplinary investigator with extensive expertise in the fields of precision-nanomedicine, immunotherapy and oncology. Through his research at IBEC (Spain, 2010-2017), he developed >20 antibody-nanoparticle conjugates for management of difficult-to-treat paediatric blood diseases. Findings resulted in 12 publications at highly-regarded nanomedicine journals (J.Control Release-2015/2016,Biomaterials-2017; 50% as first or corresponding author). His research has influenced others to develop nanomaterials against HIV and cancer (Biomolec Chemistry,2020,18,9639-9652, Acta Pharmacologica Sinica,2021,42:1516-1523). Dr. Moles joined Children's Cancer Institute in 2017, applying his translational capacity to engineer targeted nanotherapeutics for the treatment of cancer. Through UNSW-RIS 2019/2020 infrastructure funds ($923k), he established nanomedicine-dedicated infrastructure, the first of its kind at CCI/UNSW, through which he developed advanced chemo- & RNA-based lipid nanotherapeutics for the treatment of aggressive leukaemia (Pharmaceutics,2021,13:1681, Sci Transl Med,2023,15:eabm1262) and paediatric brain cancers (ongoing studies on DIPG & GBM through Moderna Global programme and a ChadTough Investigator Grant). Contributions within the nanomedicine field are further evidenced by being cited in reviews of highly-regarded journals (Adv Drug Delivery Reviews,2020,154-155:151-162, Nature Nanotechnology,2021,16:369-384), an invited editorial contribution to Nature Biomedical Engineering (2019,3:248-250). Leadership in his field is further evidenced by the award of two prestigious Moderna Fellowships (2023-2027), and a ChadTough Defeat DIPG New investigator Grant (2025-2028). Dr. Moles currently leads the mRNA immunotherapy lab where he investigates advanced mRNA-based nanotherapeutics for immune-modulation and treatment of Diffuse Midline Gliomas.
Abstracts this author is presenting: